Plant Name: Conium maculatum
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.906E-11 | 5.187E-08 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, MMP1, MMP2, MMP9, PTPN1, TP53 |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.346E-07 | 5.605E-04 | CTSD, HIF1A, MMP1, MMP2, MMP9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.391E-25 | 3.028E-21 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 9.504E-07 | 1.380E-03 | CTSD, HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 4.440E-06 | 5.742E-03 | CTSD, MMP1, MMP2, MMP9 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 7.070E-06 | 7.697E-03 | CTSD, MMP1, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.482E-06 | 7.924E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.114E-19 | 1.212E-15 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.421E-18 | 1.862E-14 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.347E-25 | 7.235E-23 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 5.956E-07 | 3.395E-05 | MMP1; MMP2; MMP9; TP53 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 3.151E-06 | 9.038E-05 | MMP1; MMP2; HIF1A; TP53; MMP9; NFKB1; MTOR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.171E-06 | 9.038E-05 | CASP7; LMNA; TP53; CTSD; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.931E-05 | 4.404E-04 | MMP2; TP53; HIF1A; MMP9; MTOR |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 1.013E-04 | 1.924E-03 | CASP7; CASP1; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.824E-04 | 2.971E-03 | TP53; HIF1A; MTOR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 4.219E-04 | 5.345E-03 | TP53; NFKB1; MTOR |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 4.953E-04 | 5.646E-03 | TP53; NFKB1; MTOR |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.549E-04 | 3.632E-03 | CASP7; CASP1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.468E-04 | 6.704E-03 | HIF1A; NFKB1; MTOR |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 7.832E-04 | 6.868E-03 | CASP7; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 7.627E-04 | 6.868E-03 | PTPN1; NFKB1; MTOR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.600E-04 | 7.427E-03 | TP53; HIF1A; MTOR |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.389E-03 | 9.313E-03 | TP53; MMP9; NFKB1; MTOR |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.008E-03 | 7.427E-03 | TP53; CTSD; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.771E-03 | 1.122E-02 | TP53; MMP9; NFKB1 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.207E-03 | 1.828E-02 | TP53; MMP9; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.981E-03 | 2.063E-02 | NFKB1; MTOR |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.402E-03 | 2.182E-02 | HIF1A; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 5.146E-03 | 2.238E-02 | TP53; MTOR |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 3.200E-03 | 1.828E-02 | CASP1; TP53 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.301E-03 | 2.238E-02 | TP53; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.981E-03 | 2.063E-02 | CASP1; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.042E-03 | 7.427E-03 | CYP1A2; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.146E-03 | 2.238E-02 | CYP1A2; ALDH1A1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 6.449E-03 | 2.451E-02 | TP53; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 4.993E-03 | 2.238E-02 | CASP1; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 5.780E-03 | 2.337E-02 | CYP1A2; CYP2C19 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.204E-02 | 3.710E-02 | MMP2; NFKB1 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 5.944E-03 | 2.337E-02 | NFKB1; MTOR |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.159E-02 | 3.710E-02 | MMP2; MMP9 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.204E-02 | 3.710E-02 | HIF1A; MTOR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 8.850E-03 | 2.967E-02 | TP53; NFKB1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 8.074E-03 | 2.930E-02 | CYP1A2; CYP2C19 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.670E-02 | 4.881E-02 | TP53; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.850E-03 | 2.967E-02 | CASP1; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.618E-02 | 4.853E-02 | MMP2; MMP9 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.224E-03 | 2.930E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; MTOR; CA9 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CTSD |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; MMP9 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MTOR; CA9; MMP9; MMP2 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | MTOR; MTOR |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | CTSD |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CASP1; MMP1 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; CA1; MTOR; CA9; MMP9; NFKB1; MMP2 |
| NA: NA | Edema | NA | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| NA: NA | Coronary artery restenosis | NA | MTOR |